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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a dreadful disease usually diagnosed in late adulthood; hence, many patients suffer from other diseases [1, 2] . PDAC patients present certain morbidities more often than non-PDAC patients, including chronic pancreatitis, type-2 diabetes mellitus (T2DM) or obesity [3] [4] [5] . Few studies focus in constellations of morbidities, and most explore associations between individual conditions and PDAC risk. In PDAC, multimorbidity has been mainly studied in the context of the metabolic syndrome (MetS), a cluster of conditions including abdominal obesity, hypertension, fasting hyperglycemia and serum hypertriglyceridemia, and low HDL cholesterol [6] . Having !3 MetS conditions has been associated with a twofold increased PDAC risk [7] ; yet, few studies have characterized in detail this relationship [8] [9] [10] [11] [12] . Additional multimorbidity patterns (MPs) affecting PDAC might exist, providing key information on disease mechanisms and contributing to the development of strategies to improve risk assessment.
We explored the patterns of co-occurrence of 17 self-reported medical conditions and their association with PDAC in a European case-control population. Identifying MPs and evaluating their effect on PDAC risk provides clues on common (genetic and/or environmental) backgrounds and allow us to obtain a finer characterization of risk. The assessment of time since diagnosis of these conditions allowed us to evaluate whether the morbidities represent a risk factor or an early manifestation of the malignancy.
Methods

Study population
The PanGenEU case-control study recruited PDAC patients !18 years old from Spain, United Kingdom, Germany, Ireland, Italy, and Sweden between 2009 and 2014 (supplementary Annex S1 and Table S2 , available at Annals of Oncology online). Italy contributed with cases only. Controls were hospital based, except in Ireland and Sweden where controls were population based. Controls had no history of PDAC and principal diagnosis at admission was unrelated to known risk factors of PDAC (supplementary Table S1 , available at Annals of Oncology online). Response rate was 86.3% in cases and 77.8% in controls. Institutional Review Board approval and written informed consent were obtained from all centers and participants.
Health monitors carried out in-person interviews; subjects answered 'yes/no' to 'Has your doctor ever told you that you had any of the following illnesses, health problems or procedures?' for 25 medical conditions (supplementary Table S3 , available at Annals of Oncology online). Obesity (body mass index, BMI !30 kg/m 2 ) was calculated using reported usual adult height and weight 2 years before recruitment. Only conditions with prevalence !2% were considered. Subjects without information in the medical questions were removed (n ¼ 268, 8.8%), leaving 1705 cases and 1084 controls. Age, sex, and smoking were not statistically different between included and excluded subjects (P >0.05).
Statistical analysis
Data were imputed using missForest R package (supplementary Methods, available at Annals of Oncology online). Adjustment variables were selected using the 10% change of estimate method. Statistical significance was considered as P <0.05. Analyses were carried out using R version 3.1.2.
All combinations of two (comorbidity) and three (trimorbidity) morbidities within an individual were considered (supplementary Methods, available at Annals of Oncology online). MPs were defined separately for cases and controls using hierarchical cluster analysis, principal component, and factor analyses (supplementary Methods, available at Annals of Oncology online). Variables were created by combining presence/absence of conditions (0 ¼ none, 1 ¼ any one, 2 ¼ any two, 3 ¼ any three or more) for gastric (Helicobacter pylori, acid regurgitation, heartburn, and ulcer), MetS (T2DM, hypertension, obesity, and hypercholesterolemia), and atopic (asthma, nasal, and skin allergies) patterns. To determine the degree of a subject belonging to the identified patterns, i.e. adherence to a pattern, factor scores were calculated: low and high adherence for the first and third tertiles, respectively. Logistic regressions were carried out to evaluate the association of each MP and adherence tertiles with PDAC. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was explored through stratification as recent (<3 years) and long term (!3 years). Variables whose associations resulted in an odds ratio (OR) change >1.5 after stratification by time since diagnosis were combined into a single variable for further analysis. Interaction between MPs and age, sex, and smoking was calculated comparing models with and without interaction terms through likelihood ratio test. Additive interactions of morbidities within each MP were also tested (supplementary Methods, available at Annals of Oncology online). Excluding patients from Italy did not modify the results. Heterogeneity by country was not significant (P >0.2). Internal validation of these models was also carried out (supplementary Methods, available at Annals of Oncology online) Multimorbidity system analysis was carried out with DisGeNET (supplementary Methods, available at Annals of Oncology online).
Results
Demographic and lifestyle information is provided in supplementary Table S2 , available at Annals of Oncology online.
Individual conditions
Number of morbidities reported was similar among cases and controls ($7% zero morbidities; $38% !4 morbidities). When comparing subjects reporting zero morbidities with those reporting !4, the former were younger (mean age 59 versus 67 years), less heavy smokers (15.5% versus 20.1%), and more commonly males (61.1% versus 53.3%).
Comorbidity assessment
Most morbidities (81%) associated with each other in the same direction in cases and controls, with only moderate differences (supplementary Figure S1 , available at Annals of Oncology online). Nine comorbidities and four trimorbidities were significantly associated with PDAC after multiple test correction (supplementary Table S4 , available at Annals of Oncology online). The strongest positive association was observed for 'T2DM and acid regurgitation' (OR, 4.25; 95% CI 2.55-7.08). The average SPP for these associations was 93.3, i.e. if the analysis was repeated 100 times, the association would be statistically significant 93 times after multiple test correction. Significant trimorbidities (average SPP, 93.4) always included T2DM and a combination of other conditions with ORs around 4, suggesting that the association of T2DM with PDAC risk might be potentiated by some morbidities.
Multimorbidity assessment
Three clear patterns of conditions emerged: (i) gastric: heartburn, acid regurgitation, H. pylori, and ulcer; (ii) MetS: obesity, T2DM, hypercholesterolemia, and hypertension; and (iii) atopic: nasal allergies, skin allergies, and asthma ( Figure 1 ). The remaining conditions did not follow a consistent pattern of co-occurrence and were not considered in further analyses.
A positive association was observed between PDAC risk and the gastric and MetS patterns with a positive trend (P <0.01); a negative association was observed in the atopic pattern (Table 1) . Similar findings were observed when comparing the highest with the lowest adherence tertiles. An interaction was observed between MetS and sex; !3 MetS conditions was associated with PDAC in males but not in females (P ¼ 0.032; supplementary Table S5 , available at Annals of Oncology online).
Time since diagnosis
Associations do not necessarily indicate causality; therefore, we assessed the associations in relation to the period since diagnosis of conditions and PDAC. Recent diagnosis of the gastric pattern showed stronger association with PDAC risk than long-term diagnosis (OR 6.13; 95% CI 3.01-12.5 and OR, 1.17; 95% CI, 0.79-1.73, respectively). Stratification of the MetS pattern was done based of T2DM diagnosis because the other conditions did not show different associations with PDAC by time since diagnosis: OR, 1.61; 95%CI, 1.11-2.35 for recent and OR, 1.35; 95% CI, 0.99-1.85 for long-term diagnosis. This analysis could not be carried out for the atopic pattern because time since diagnosis was only available for asthma.
Gastric MP and T2DM showed the greatest change in their association with PDAC after stratification by time since diagnosis (supplementary Table S3 , available at Annals of Oncology online). Tertiles of factor scores on the overall group of cases and controls. High adherence (tertile III) compared with low adherence (tertile I). e MetS pattern: obesity, T2DM, hypercholesterolemia and hypertension. f Atopic pattern: skin allergies, nasal allergies, and asthma. Time since diagnosis was not available for nasal and skin allergies.
Considered altogether, having !1 of these was strongly associated with PDAC among subjects with recent diagnosis (OR, 7.89; 95% CI 3.9-16.1 for !2 conditions) while a moderate estimate was observed among subjects with long-term diagnosis (OR 1.86; 95% CI 1.29-2.67 for !3 conditions; Table 2 ). The average AUC for this model was 0.78 (SD¼ 0.011) for recently diagnosed conditions; and 0.72 (SD¼ 0.01) and 0.74 (SD¼ 0.009) for long-term and lifetime models, respectively (data not shown). Treating obesity as a confounder showed similar results (supplementary Table  S6 , available at Annals of Oncology online).
Bioinformatics analysis showed a stronger genetic link among morbidities included in the metabolic and atopic patterns in comparison to those of the gastric pattern, possibly due to less reported disease-gene associations in the latter. All patterns shared genetic links with PDAC (supplementary Figure S2 , available at Annals of Oncology online), and many of these conditions shared inflammatory related genes such as TNF, CXCL8, HIF1A, and PTGS2 (supplementary Figure S3 , available at Annals of Oncology online).
Discussion
We analyzed the aggregation and association of 17 self-reported medical conditions with PDAC risk in a large case-control European study. We identified three MPs: the gastric and MetS patterns, positively associated with PDAC, and the atopic pattern, negatively associated. Moreover, we explored MPs in the temporal context of pancreatic cancer which provides clues about common mechanisms and causal effect.
Among the gastric pattern, sensitivity analysis showed that heartburn and acid regurgitation had the strongest effect on the association. In the MetS pattern, T2DM was the main driving condition since removing T2DM from the pattern resulted in loss of significance. In the atopic pattern, none of the conditions seemed to drive the association individually.
Associations between gastric and MetS patterns with PDAC were significant only among subjects with recently diagnosed conditions. Our results strengthen previous findings with smaller case sample size or pooled heterogeneous populations reporting positive associations between history of gastric or duodenal ulcer with PDAC only among recently diagnosed subjects [2, 13, 14] . Two cohort studies reported a significant association between PDAC and long-term diagnosis (up to 20 years) of gastric but not of duodenal ulcer [15, 16] ; whether gastric ulcer was related to H. pylori infection was not elucidated. A recent meta-analysis including 10 case-control studies reported a non-significant association between overall H. pylori infection and PDAC [17] . These studies did not consider time since diagnosis and are limited in their ability to assess causality. Less information exists for acid regurgitation or heartburn. One study reported a significant positive association between PDAC and episodes of !4 weeks of heartburn up to 5 years before cancer diagnosis/interview [18] . For the MetS pattern, this observation was attributed to T2DM confirming and extending previous reports of a stronger positive association among new-onset diabetics [4, 19] . Importantly, the significant association between three or more MetS conditions and PDAC was restricted to males, pointing to a potential role of BMI since, contrary to females, there were more obese males among cases (22.6%) than among controls (18.9%). Previous studies reported contradictory results on the interaction between MetS and sex [7, 8, 11, 12] , more studies are needed to confirm our observations. Although recent asthma diagnosis was reported by <1%, long-term asthmatics were negatively associated with PDAC. Consistently, a significant inverse association between PDAC and nasal allergies unrelated to disease duration has been reported [20] . Five conditions (i.e. T2DM and gastric conditions) stood out by the magnitude of OR change after stratification by time since diagnosis. When consolidated into a single variable, a stronger positive association was observed between having !1 of these conditions recently diagnosed and PDAC. T2DM was an important driver of this association, but having !3 of these conditions showed a stronger estimate than by T2DM alone highlighting the potential significance of combining morbidities when studying PDAC. Bootstrapped AUCs showed a fair performance of the models including these five conditions; restriction to recent diagnosis resulted in the best performance. Conceivably, additive interactions between morbidities within MPs could explain these results. In this regard, we observed a significant additive interaction between asthma and both nasal and skin allergies and a significant sub-additive interaction between diabetes and the combination of any three or more gastric conditions; however, we were limited by sample size in these analyses. Mechanistically, these associations might be explained in the context of systemic inflammation: early events during PDAC carcinogenesis could favor the development of type-3c diabetes, altogether prompting dysbiosis which could, in turn, be manifested as gastric conditions. Further analysis showed an intricate genetic system among the MPs and pancreatic cancer pointing to a potential mechanistic link between these (supplementary Figures S2 and S3 , available at Annals of Oncology online).
It has been hypothesized that PDAC development might occur during the 10 years previous to its detection with disease manifestations in the preceding 1-2 years. Yet, there are arguments in favor of a rapid 'catastrophic' evolution shortly before diagnosis [21] . We aimed at discriminating medical conditions acting as true risk/protective factors (long-term diagnosis) versus early manifestations of PDAC (recent diagnosis). We show that longterm T2DM and asthma are associated with PDAC, pointing to them as true risk and protective factors, respectively. Interestingly, the co-occurrence of long-term T2DM with longterm gastric conditions was associated with a stronger PDAC risk than that conferred by T2DM alone indicating that while T2DM is a main risk factor of PDAC, its overlap with other gastric conditions might further aggravate carcinogenesis. We also provide strong evidence that several conditions associate with PDAC risk only when diagnosed shortly before PDAC, suggesting that these could be PDAC manifestations. This concept has been discussed in the context of T2DM [4, 13, 19, 22, 23] , and it is further supported by studies showing improvement of insulin resistance and glucose intolerance after PDAC resection [24, 25] . However, we cannot rule out that pathophysiologically distinct subtypes of T2DM and/or other conditions might accelerate PDAC progression resulting in a shorter time between diagnoses.
Early PDAC diagnosis provides the only opportunity for longterm survival. Establishing a set of conditions alerting the clinical staff of potential PDAC cases could improve diagnosis, management, and/or treatment of patients and consequently, the outcome of the disease. However, the symptoms/conditions here described are relatively nonspecific hindering their immediate adscription to PDAC. Moreover, whether PDAC stage at diagnosis modifies the reported associations deserves further investigation. While innovative and detailed analyses have been carried out to both identify MPs and to assess their risk with PDAC, bias by unmeasured confounders is always a concern (i.e. metformin or statins medications have been associated with decreased risk of PDAC). Future studies should focus on exploring the role of particular treatments in these associations.
Our study has some limitations. The information was selfreported, thus misclassification and bias cannot be completely ruled out; nevertheless, the consistency of basic findings in this report with existing literature argues against this possibility. Our study is one of the largest performed, but-despite its size and the restriction of our analyses to conditions with a frequency !2% in cases and controls-statistical power remains an issue when considering multimorbidities and stratification by time since diagnosis.
To our knowledge, this is the first study that simultaneously considers the association of many morbidities with PDAC. We report three main MPs significantly associated with PDAC and show that the associations change depending on the time since diagnosis of morbidities. Owing the high prevalence of multimorbidities, evaluating MPs may help to improve the characterization of PDAC risk. Confirmation of these results in independent studies will be critical in their generalization and future clinical application. Identification of early manifestations of PDAC may help define subpopulations of patients in whom screening might be cost-effective [26] . Moreover, the discovery of risk and protective associations should lead to more pathophysiological studies. Thus, the knowledge generated could contribute to implement novel preventive and therapeutic strategies.
